The vaccine COVISHIELD was administered to the first volunteer by the superintendent of KGH and principal of Andhra Medical College, Dr. PV Sudhakar. File | Photo Credit: Special arrangement
“It felt like a tetanus shot,” said Joel Joy, 32, who works for a multinational firm in Mumbai, and was among those who’d volunteered for the experimental Covishield vaccine, being tested by the Pune-based Serum Institute of India (SII) at various hospitals in India, “I'll be going to the gym later today,” he added.
The two-dose vaccine candidate is furthest ahead among the COVID-19 vaccines being tested in India. The trial involves 1,600 volunteers in 17 cities across the country likely to be inoculated in the coming months in the combined phase-2/3 trials. These trials check for whether the vaccine is safe and capable of producing an immune response to disarm future infections by the SARS-CoV-2 virus.
According to details of the trial available on the Indian Council of Medical Research (ICMR) site, the volunteers will be divided into two groups of 400 and 1,200 respectively with some in each group getting Covishield, some a placebo and yet others getting the Oxford/ChAdOx1. Both ‘Covishield’ and the Oxford/ChAdOx1 have the same virus protein but differ in their make-up — the exact nature of the difference has not been publicly disclosed. The trial also seeks to quantify these differences if any.
Social activist and Mumbai-based entrepreneur, Anil Hebbar, 56, also among the volunteers for the trial at the KEM hospital in Mumbai, said that after the vaccine, he felt nothing out of the ordinary other than a slight weariness.
“It was painless. I usually sleep after 1 a.m. and am up by 6 a.m. and travel extensively through the day and never feel particularly tired. But post the injection in the past four days, I feel a little extra tired,” he told The Hindu.
Being a double-blinded trial, neither the doctors nor the volunteers know who are the ones vaccinated and who've been given the placebo. The four volunteers who The Hindu spoke to, said they would be going for a follow-up shot on the 29th day.
Each of the inoculates involves 0.5 ml of the test-medicine being administered in a four-week interval. After a jab, a day’s dose of paracetamol is given to keep possible fever in check.
None of the participants said they registered a fever or a rash or itchiness at the site of the inoculation (the upper fore-arm).
“It was an ordinary experience and I was done in 30 minutes,” said Vaishali Janardhanan, 27, a volunteer and a social activist. “I was scrolling my phone during the shot. There were three women doctors on standby and because I was a woman, the 'pre-screening' involved a pregnancy test,” she said.
While anyone above 18 can volunteer, those who end up being part of a trial are pre-screened for a previous COVID infection as well as have their vitals examined.
At least one person, who was part of the Oxford vaccine trial in the United Kingdom and was administered the vaccine, suffered transverse myelitis, or an inflammation of the spinal cord due to which the trials were paused globally for reviews by safety boards. Trials have since resumed. All of the volunteers who spoke to The Hindu said they were made aware of these risks but were unperturbed.
“My parents were a little sceptical but I had no doubt. With COVID it’s now a matter of WHEN you will be infected rather than IF, given the spread we are seeing. Volunteering is the bare minimum I can do to help the world get a vaccine,” said Ms. Janardhanan.
Mr. Hebbar, Mr. Joy and Ms. Janardhanan said they were regularly involved in relief work and in organising supplies, donating blood and saw participation in the trial as an extension of what they always did.
Dr Rahul Ghule, a paediatrician, who was also vaccinated, said he planned to go for an antibody test in a month. Assuming the vaccine works as intended and a person didn't get a placebo, protective antibodies in response to the virus are expected to emerge in a month. However, it's still uncertain how long they would last and realistically confer protection.
Source - The Hindu
Adar Poonawalla, CEO, Serum Institute of India, receives the award for the Outstanding Business Leader of the Year
Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in the Philippines
Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in Indonesia
Serum Institute Of India sends out Covishield vaccine - Consignment of Covishield Vaccine arrived in Delhi, Chennai, Kolkata, Guwahati, Shillong, Ahmedabad, Hydrabad, Vijayawada, Bhubaneswar, Patna, Bengaluru, Lucknow, Chandigarh
Serum Institute of India launches India’s first fully indigenously developed pneumococcal vaccine, 'PNEUMOSIL'
Oxford COVID-19 vaccine: Serum Institute likely to submit final Covishield trial data within 10 days
SII’s Adar Poonawalla on Covid vaccine, pricing and rollout at Hindustan Times Leadership Summit 2020
COVISHIELD Completes Enrolment of Phase III clinical trials under partnership of ICMR and Serum Institute of India
Government Secures Vaccine Supplies For Half Of The Indian Population From Serum Institute And Novavax
IAVI, Merck, and Serum Institute of India Join Forces to Develop Monoclonal Antibodies for COVID-19 and Ensure Prompt and Equitable Global Access
Serum Institute Of India Takes A Multipronged Approach In Quest To Produce World’s First Covid-19 Vaccines
Serum Institute of India to produce up to an additional 100 million covid 19 vaccine doses for india and low and midle income countries in 2021
Adar Poonawalla CEO of Serum Institute of India, the world’s largest vaccine manufacturer, explains the timing, challenges & cost of vaccinating the world against COVID-19
Serum Institute looking for a $1 billion shot to fight covid, talks on with Blackstone, KKR and others
Serum Institute of India Says Covid Vaccine Likely to Be Ready by End of 2020, Final Pricing in 2 Months
Serum institute of india to produce up to 100 million covid-19 vaccine doses for india and low-and middle-income countries as early as 2021
50% of our Covid vaccines will be for India, people won't have to buy them, govts will pay: Adar Poonawalla
AstraZeneca vaccine's success in early human trials, Will Begin AstraZeneca Vaccine Trial in India After Applying for Licence Next Week, Says Serum Institute
Serum Institute of India CEO: ‘We plan to make millions of doses of Covid vaccine over three months’:’
New supply agreement between UNICEF and Serum Institute of India makes pneumococcal conjugate vaccine available at US$2.00 per dose, a 43 % reduction from the Gavi price at the start of the Advance Market Commitment
Serum Institute confident of manufacturing Covid vaccine’s 100 million doses if trials establish efficacy
Serum Institute’s Journey To Success | ET NOW Covid-19 vaccine possible by Q2 of 2022: Adar Poonawalla
Adar Poonawalla discusses Serum Institute's progress in the global battle against COVID-19 with Shereen Bhan, CNBC-TV18
Adar Poonawalla talks with Aabha Bakaya about the success story of Serum Institute of India. Tune in to know all about the journey of the company.
Bill Gates confers Indian Council of Medical Research "Lifetime Achievement Medal" on Dr. Cyrus Poonawalla
Dr. Cyrus Poonawalla conferred with 'Lifetime Achievement Award’ by the Asian Business Leadership Forum
Dr. Cyrus Poonawalla conferred with the prestigious honorary degree by the University of Oxford, U.K.